Within the TGFβ pathway, loss of function mutations are most common, particularly in gastrointestinal cancers [91], notably in pancreatic cancers and colorectal cancers (up to 100% and 83% of patients respectively) [92,93]. This evidence concerns the gene TGFB1 and colorectal cancer.